The Journal of Urology
Volume 182, Issue 5 , Pages 2188-2194 , November 2009

A Novel Approach to Using Matrix Metalloproteinases for Bladder Cancer

  • Cecilia A. Fernández

      Affiliations

    • Financial interest and/or other relationship with Predictive Biosciences.
    • Predictive Biosciences, Inc., Lexington, Massachusetts
    • ,
  • Matthew F. Wszolek

      Affiliations

    • Department of Urology, Lahey Clinic Medical Center, Burlington, Massachusetts
    • ,
  • Kevin R. Loughlin

      Affiliations

    • Financial interest and/or other relationship with Predictive Biosciences.
    • Division of Urology, Harvard Medical School-Brigham and Women's Hospital, Boston, Massachusetts
    • ,
  • John A. Libertino

      Affiliations

    • Department of Urology, Lahey Clinic Medical Center, Burlington, Massachusetts
    • ,
  • Ian C. Summerhayes

      Affiliations

    • Department of Urology, Lahey Clinic Medical Center, Burlington, Massachusetts
    • ,
  • Anthony P. Shuber

      Affiliations

    • Financial interest and/or other relationship with Predictive Biosciences.
    • Predictive Biosciences, Inc., Lexington, Massachusetts
    • Corresponding Author InformationCorrespondence: 128 Spring St., Lexington, Massachusetts 02142

Received 5 March 2009

References 

  1. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784
  2. Cancer Facts and Figures 2007. Oklahoma City: American Cancer Society; 2007;
  3. Dalbagni G. The management of superficial bladder cancer. Nat Clin Pract Urol. 2007;4:254
  4. Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol. 2006;50:1176
  5. Josephson DY, Pasin E, Stein JP. Superficial bladder cancer: part 1 (Update on etiology, classification and natural history). Expert Rev Anticancer Ther. 2006;6:1723
  6. Kitamura H, Tsukamoto T. Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol. 2006;11:28
  7. Sharir S. Update on clinical and radiological staging and surveillance of bladder cancer. Can J Urol. 2006;13(suppl.):71
  8. Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. Sci World J. 2006;6:2617
  9. Bladder Cancer Including Upper Tract Tumors and Urothelial Carcinoma of the Prostate. In: Fort Washington, Pennsylvania: National Comprehensive Cancer Network; 2008;p. 1–44
  10. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43(suppl.):S42
  11. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells. 1997;15:180
  12. Eissa S, Ali-Labib R, Swellam M, et al. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol. 2007;52:1388
  13. Fernandez CA, Yan L, Louis G, et al. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005;11:5390
  14. Moses MA, Wiederschain D, Loughlin KR, et al. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998;58:1395
  15. Smith ER, Manfredi M, Scott RM, et al. A recurrent craniopharyngioma illustrates the potential usefulness of urinary matrix metalloproteinases as noninvasive biomarkers: case report. Neurosurgery. 2007;60:E1148
  16. Smith ER, Zurakowski D, Saad A, et al. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res. 2008;14:2378
  17. Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2003;21:1315
  18. Brown ML, Finter L. The economic burden of cancer. In:  Greenwald P,  Kramer BS,  Weed DL editor. Cancer Prevention and Control. New York: Marcel-Dekker; 1995;p. 69–81
  19. Hong YM, Loughlin KR. Economic impact of tumor markers in bladder cancer surveillance. Urology. 2008;71:131
  20. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561

 Study received institutional review board approval.

PII: S0022-5347(09)01761-3

doi: 10.1016/j.juro.2009.07.032

The Journal of Urology
Volume 182, Issue 5 , Pages 2188-2194 , November 2009

Article Tools

* Image Usage & Resolution